• Yuval Bitterman, Evyatar Hubara, Amir Hadash, Josef Ben-Ari, Gail Annich, and Danny Eytan.
• Department of Pediatric Critical Care, Rambam Healthcare Campus, Haifa, Israel.
• Isr Med Assoc J. 2020 Jul 1; 22 (7): 404-408.

BackgroundMethylene blue (MB), an inhibitor of nitric oxide synthesis and its effects is a potentially effective treatment against distributive shock states such as septic shock and vasoplegic syndrome. MB has been shown to alleviate vasoplegia and promote an increase in blood pressure. It may reduce mortality. However, in the pediatric population, there are few case reports and only one controlled study on administration of MB use for vasoplegia, sepsis, or shock in general.ObjectivesTo summarize the experience of administering MB for vasoplegic shock in a tertiary care pediatric intensive care unit.MethodsA retrospective chart review of seven pediatric cases treated with MB for vasoplegic shock was conducted. MB was administered as a bolus followed by continuous infusion. The authors measured blood pressure, vasopressor, and inotropic support. Patient outcome was monitored.ResultsThe authors observed a favorable hemodynamic response with an increase in blood pressure and a reduction in vasopressor and inotropic support needed following MB administration in six patients. No side effects were observed. Three patients eventually died one to two days later, secondary to their underlying disease.ConclusionsThis case series adds to the small body of evidence in the pediatric population supporting the use of MB for distributive shock states and emphasizes the need for larger, randomized trials evaluating its role in vasoplegic shock treatment.

32 keywords...

hide…